Literature DB >> 231445

Cyclophosphamide cystitis. Studies aimed at its minimization.

P J Cox, G Abel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 231445     DOI： 10.1016/0006-2952(79)90390-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  5 in total

1.  Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice.

Authors:  J D Roberts; M P Hacker; R A Newman; J J McCormack; I H Krakoff
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

2.  Preclinical pharmacokinetics and stability of isophosphoramide mustard.

Authors:  J J Zheng; K K Chan; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Rescue of rats from large dose cyclophosphamide toxicity using protein A.

Authors:  P K Ray; M Dohadwala; S K Bandyopadhyay; P Canchanapan; D McLaughlin
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Cysteine Supplementation Mitigates the Toxicity Associated with Antitumor Therapy of Ehrlich's Ascites Fluid Adsorbed over Protein A Containing Staphylococcus aureus Cowan I.

Authors:  Ashish S Verma; Anchal Singh; Priyadarshini Mallick; Premendra D Dwivedi
Journal:  J Pharm Bioallied Sci       Date:  2019 Jan-Mar

5.  Exogenous supplementation of N-acetylcysteine Can Reduce Hepatotoxicity Induced by Ascites Fluid (Cell-Free) Adsorbed Over Protein-A-Containing Staphylococcus aureus Cowan-I Without Compromising Its Antitumor Effect.

Authors:  Ashish S Verma; Priyadarshini Mallick; Premendra D Dwivedi; Anchal Singh
Journal:  J Pharm Bioallied Sci       Date:  2019 Jul-Sep
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.